Advances in Lymphoma
Transcript: Lymphoma therapies at ESMO 2024
Professor Andrés Ferreri
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
There are several new therapeutic strategies with different pharmacodynamic mechanisms. Most of them are used like in the past, before for solid tumours, and then they were moved to the treatment of lymphoma patients, and vice versa.
There are situations like those of the CAR T-cells that are first developed against lymphomas, and then moving for the treatment of the solid tumours. I think that it will be the case also in this congress. One of the most interesting studies is the use of vaccines, in particular, anti-ABB vaccines, that are used in very aggressive lymphomas, the NK/T-cell lymphomas that are strongly driven by the infection of the Epstein Barr Virus. And there was a first phase 1B trial developed in China where the patients received this vaccination, and half of the treated patients achieved a partial response, which is encouraging also because the vaccine were well-tolerated without any side effect. Obviously, this strategy will not be able to interrupt the progression of these very aggressive lymphomas, but probably it will be used as part of the first-line treatment, as adjuvant treatment, to reduce the risk of relapsing disease.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event